Protalix BioTherapeutics, Inc. Effective Tax Rate
Protalix BioTherapeutics, Inc. (PLX) reported Effective Tax Rate of -18.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateContinuingOperations · last filed 2026-03-18
- Protalix BioTherapeutics, Inc. effective income tax rate reconciliation, percent for the quarter ending 2025-03-31 was 3.00%, a 0.00% change year-over-year.
- Protalix BioTherapeutics, Inc. effective income tax rate reconciliation, percent for the quarter ending 2024-03-31 was 3.00%, a 57.14% decline year-over-year.
- Protalix BioTherapeutics, Inc. effective income tax rate reconciliation, percent for the quarter ending 2023-03-31 was 7.00%.
- Protalix BioTherapeutics, Inc. effective income tax rate reconciliation, percent for fiscal 2025 was -18.00%.
- Protalix BioTherapeutics, Inc. effective income tax rate reconciliation, percent for fiscal 2023 was 3.00%.
- Protalix BioTherapeutics, Inc. effective income tax rate reconciliation, percent for fiscal 2022 was -4.00%.
| Period end | Effective Income Tax Rate Reconciliation, Percent 3 month | Effective Income Tax Rate Reconciliation, Percent 3 month as first filed | Effective Income Tax Rate Reconciliation, Percent 6 month | Effective Income Tax Rate Reconciliation, Percent 6 month as first filed | Effective Income Tax Rate Reconciliation, Percent 9 month | Effective Income Tax Rate Reconciliation, Percent 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | -18.00% 10-K · filed 2026-03-18 | |||||
| 2025-09-30 | -32.00% 10-Q · filed 2025-11-13 | |||||
| 2025-06-30 | -13.00% 10-Q · filed 2025-08-14 | |||||
| 2025-03-31 | 3.00% 10-Q · filed 2025-05-09 | |||||
| 2024-09-30 | -13.00% 10-Q · filed 2025-11-13 | |||||
| 2024-06-30 | 3.00% 10-Q · filed 2025-08-14 | -3.00% 10-Q · filed 2024-08-14 | ||||
| 2024-03-31 | 3.00% 10-Q · filed 2025-05-09 | -3.00% 10-Q · filed 2024-05-10 | ||||
| 2023-12-31 | 3.00% 10-K · filed 2024-03-14 | |||||
| 2023-09-30 | 4.00% 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | 7.00% 10-Q · filed 2024-08-14 | 3.00% 10-Q · filed 2023-08-07 | ||||
| 2023-03-31 | 7.00% 10-Q · filed 2024-05-10 | |||||
| 2022-12-31 | -4.00% 10-K · filed 2024-03-14 | |||||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-06 | |||||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |